While patients often
improve on the drug and live longer than they would on standard treatment (results will be presented Sunday at ASCO), the drug,
vemurafenib, usually stops working within a year.
The combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib yielded
improved progression - free survival over
vemurafenib in a phase III trial of patients with advanced BRAF V600 — mutant melanoma.